Tyra Biosciences, Inc.·4

Feb 13, 4:30 PM ET

Bensen Daniel 4

4 · Tyra Biosciences, Inc. · Filed Feb 13, 2026

Research Summary

AI-generated summary of this filing

Updated

Tyra Biosciences (TYRA) Chief Discovery Officer Daniel Bensen Sells Shares

What Happened
Daniel Bensen, Chief Discovery Officer of Tyra Biosciences (TYRA), sold a total of 8,000 shares in two open‑market transactions on February 12, 2026, generating combined proceeds of approximately $262,965. The sales broke down as 2,128 shares at a weighted average price of $31.50 (≈ $67,036) and 5,872 shares at a weighted average price of $33.37 (≈ $195,929). These were sales (not purchases), which are commonly routine disposals rather than a direct bullish signal.

Key Details

  • Transaction date: February 12, 2026; Form 4 filed February 13, 2026 (appears timely).
  • Shares sold: 2,128 @ $31.50 (weighted avg; actual prices $31.02–$31.75) and 5,872 @ $33.37 (weighted avg; actual prices $32.98–$33.85).
  • Total shares sold: 8,000; total proceeds: ~$262,965.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted November 5, 2024. Exact per‑trade price breakdowns are available from the issuer on request.
  • Transaction code: S = Sale.

Context
Sales executed under a pre‑arranged 10b5‑1 plan are scheduled trades intended to avoid timing based on inside information; they are common among executives and often indicate routine portfolio management rather than a view on the company’s prospects. For retail investors, purchases typically carry more direct informational value than routine insider sales.

Insider Transaction Report

Form 4
Period: 2026-02-12
Bensen Daniel
Chief Discovery Officer
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-02-12$31.50/sh2,128$67,036152,853 total
  • Sale

    Common Stock

    [F1][F3]
    2026-02-12$33.37/sh5,872$195,929146,981 total
Footnotes (3)
  • [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
  • [F2]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  • [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact|2026-02-13

Documents

1 file
  • 4
    ownership.xmlPrimary

    4